↓ Skip to main content

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group

Overview of attention for article published in BMC Cancer, October 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
1 X user
wikipedia
1 Wikipedia page

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
21 Mendeley
Title
Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group
Published in
BMC Cancer, October 2015
DOI 10.1186/s12885-015-1697-8
Pubmed ID
Authors

J. Khalifa, M. Ouali, L. Chaltiel, S. Le Guellec, A. Le Cesne, J-Y Blay, P. Cousin, L. Chaigneau, E. Bompas, S. Piperno-Neumann, B. Bui-Nguyen, M. Rios, J-P Delord, N. Penel, C. Chevreau

Abstract

Advanced malignant solitary fibrous tumors (SFTs) are rare soft-tissue sarcomas with a poor prognosis. Several treatment options have been reported, but with uncertain rates of efficacy. Our aim is to describe the activity of trabectedin in a retrospective, multi-center French series of patients with SFTs. Patients were mainly identified through the French RetrospectYon database and were treated between January 2008 and May 2013. Trabectedin was administered at an initial dose of 1.5 mg/m(2), q3 weeks. The best tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors 1.1. The Kaplan-Meier method was used to estimate median progression-free survival (PFS) and overall survival (OS). The growth-modulation index (GMI) was defined as the ratio between the time to progression with trabectedin (TTPn) and the TTP with the immediately prior line of treatment (TTPn-1). Eleven patients treated with trabectedin for advanced SFT were identified. Trabectedin had been used as second-line treatment in 8 patients (72.7 %) and as at least third-line therapy in a further 3 (27.3 %). The best RECIST response was a partial response (PR) in one patient (9.1 %) and stable disease (SD) in eight patients (72.7 %). Disease-control rate (DCR = PR + SD) was 81.8 %. After a median follow-up of 29.2 months, the median PFS was 11.6 months (95 % CI = 2.0; 15.2 months) and the median OS was 22.3 months (95 % CI = 9.1 months; not reached). The median GMI was 1.49 (range: 0.11-4.12). Trabectedin is a very promising treatment for advanced SFTs. Further investigations are needed.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 1 5%
Unknown 20 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 19%
Researcher 4 19%
Student > Postgraduate 3 14%
Other 3 14%
Student > Doctoral Student 1 5%
Other 0 0%
Unknown 6 29%
Readers by discipline Count As %
Medicine and Dentistry 10 48%
Biochemistry, Genetics and Molecular Biology 1 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Computer Science 1 5%
Agricultural and Biological Sciences 1 5%
Other 0 0%
Unknown 7 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2016.
All research outputs
#6,962,756
of 22,830,751 outputs
Outputs from BMC Cancer
#1,839
of 8,305 outputs
Outputs of similar age
#85,882
of 279,238 outputs
Outputs of similar age from BMC Cancer
#54
of 234 outputs
Altmetric has tracked 22,830,751 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 8,305 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,238 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 234 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.